Phase II Talazoparib in BRCA1 + BRCA2 Wild Type or Triple-Neg or HER2-Neg Breast Cancer/Solid Tumors

Trial ID or NCT#

NCT02401347

Status

not recruiting iconNOT RECRUITING

Purpose

The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific genetic or tumor genomic alterations. Patients with either triple-negative or HER2-negative breast cancer are eligible.

Official Title

A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild Type Patients With Advanced Triple Negative Breast Cancer and Homologous Recombination Deficiency or Advanced HER2 Negative Breast Cancer or Other Solid Tumors With a Mutation in Homologous Recombination Pathway Genes

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Melinda L. Telli, M.D.
Melinda L. Telli, M.D.
Medical oncologist, Breast specialist
Professor of Medicine (Oncology)

Contact us to find out if this trial is right for you.

Contact

Anastasia L Harper
650-725-0378

View on ClinicalTrials.gov